Jason Scott Slakter - Net Worth and Insider Trading
Jason Scott Slakter Net Worth
The estimated net worth of Jason Scott Slakter is at least $2,139 dollars as of 2024-12-15. Jason Scott Slakter is the CEO of NeuBase Therapeutics Inc and owns about 5,659 shares of NeuBase Therapeutics Inc (NBSE) stock worth over $2,139. Details can be seen in Jason Scott Slakter's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jason Scott Slakter has not made any transactions after 2017-04-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Jason Scott Slakter
Jason Scott Slakter Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jason Scott Slakter owns 1 companies in total, including NeuBase Therapeutics Inc (NBSE) .
Click here to see the complete history of Jason Scott Slakter’s form 4 insider trades.
Insider Ownership Summary of Jason Scott Slakter
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NBSE | NeuBase Therapeutics Inc | 2017-04-10 | director |
Jason Scott Slakter Latest Holdings Summary
Jason Scott Slakter currently owns a total of 1 stock. Jason Scott Slakter owns 5,659 shares of NeuBase Therapeutics Inc (NBSE) as of April 10, 2017, with a value of $2,139.
Latest Holdings of Jason Scott Slakter
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NBSE | NeuBase Therapeutics Inc | 2017-04-10 | 5,659 | 0.38 | 2,139 |
Holding Weightings of Jason Scott Slakter
Jason Scott Slakter Form 4 Trading Tracker
According to the SEC Form 4 filings, Jason Scott Slakter has made a total of 0 transactions in NeuBase Therapeutics Inc (NBSE) over the past 5 years. The most-recent trade in NeuBase Therapeutics Inc is the acquisition of 357 shares on April 10, 2017, which cost Jason Scott Slakter around $100,001.
Insider Trading History of Jason Scott Slakter
- 1
Jason Scott Slakter Trading Performance
GuruFocus tracks the stock performance after each of Jason Scott Slakter's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jason Scott Slakter is -6.52%. GuruFocus also compares Jason Scott Slakter's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jason Scott Slakter within 3 months outperforms 1 times out of 10 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Jason Scott Slakter's insider trading performs compared to the benchmark.
Performance of Jason Scott Slakter
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 1.22 | | | | | |
| Relative Return to S&P 500(%) | 0.94 | | | | | |
Jason Scott Slakter Ownership Network
Ownership Network List of Jason Scott Slakter
Ownership Network Relation of Jason Scott Slakter
Jason Scott Slakter Owned Company Details
What does NeuBase Therapeutics Inc do?
Who are the key executives at NeuBase Therapeutics Inc?
Jason Scott Slakter is the director of NeuBase Therapeutics Inc. Other key executives at NeuBase Therapeutics Inc include 10 percent owner Symetryx Corp , 10 percent owner Barry Shiff , and 10 percent owner Aleta Shiff .
NeuBase Therapeutics Inc (NBSE) Insider Trades Summary
Over the past 18 months, Jason Scott Slakter made no insider transaction in NeuBase Therapeutics Inc (NBSE). Other recent insider transactions involving NeuBase Therapeutics Inc (NBSE) include a net sale of 428,444 shares made by Symetryx Corp ,
In summary, during the past 3 months, insiders sold 0 shares of NeuBase Therapeutics Inc (NBSE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 489,520 shares of NeuBase Therapeutics Inc (NBSE) were sold and 61,076 shares were bought by its insiders, resulting in a net sale of 428,444 shares.
NeuBase Therapeutics Inc (NBSE)'s detailed insider trading history can be found in Insider Trading Tracker table.
NeuBase Therapeutics Inc Insider Transactions
Jason Scott Slakter Mailing Address
Above is the net worth, insider trading, and ownership report for Jason Scott Slakter. You might contact Jason Scott Slakter via mailing address: 57 Meadow Woods Road, Great Neck Ny 11020.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
